Trial Information
Pediatric brain cancer is relatively rare. However, cancer is the leading cause of death by disease among children in the U.S. Brain and spinal cord tumors are the 2nd most common cancers in children, accounting for ~26% of childhood cancers.
Plus Therapeutics is developing the REYOBIQ™ (rhenium Re186 obisbemeda) radiotherapeutic for the treatment of rare, frequently fast-growing pediatric brain and spinal cord tumors with a poor prognosis – ependymoma and high-grade glioma (HGG) in a study known as the ReSPECT-PBC (Pediatric Brain Cancer) U.S. Phase 1 Clinical Trial. If you are interested in learning more, please fill out the form above.

Single Group
- All patients who enroll in the trial will receive medication while on the study.
- All patients will receive a single dose of REYOBIQ™ (rhenium Re186 obisbemeda).

Phase 1
- A Phase 1 study is the first step in testing a new treatment in humans. A phase I clinical trial tests the safety, side effects, best dose, and timing of a new treatment. It may also test how the treatment affects the body. The dose is usually increased a little at a time in order to find the highest dose that does not cause harmful side effects. Phase I clinical trials usually include only a small number of patients who have not been helped by other treatments.

Progress
- Anticipated Study Start: July 2025
- Estimated Phase 1 Completion: TBD (the date that the last participant in a clinical study is examined or receives an intervention and that data for the primary outcome measure is collected)
- Estimated Study Completion: TBD (the date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events, that is, the last participant's last visit).
Plus Therapeutics is evaluating REYOBIQ™ (rhenium Re186 obisbemeda), a novel radiotherapy for patients with Pediatric Brain Cancer in a Phase 1 clinical trial.
Watch now to learn more.
Principal Investigators
There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.
Ashley Plant, M.D.
Lurie Children’s Hospital of Chicago
Chicago, Illinois
SPECIALTIES: CANCER & BLOOD DISORDERS
Dr. Plant is currently an attending physician in neuro-oncology at Ann and Robert H. Lurie Children’s Hospital of Chicago and Assistant Professor at Northwestern University Feinberg School of Medicine with a research focus on translational research and early clinical trial development for pediatric brain tumors. Currently, brain tumors are the second most common cancer diagnosis in children and the leading cause of cancer-related death in all pediatric age groups. Many children diagnosed with malignant brain tumors face a dismal prognosis at diagnosis with minimal effective treatments available. Early clinical trial development and translational research is crucial to the improvement of outcomes in pediatric neuro-oncology. Dr. Plant spent her fellowship research years in the laboratories of Glenn Dranoff, MD PhD and Jerome Ritz, MD at Dana Farber Cancer Institute focusing on immunophenotyping of pediatric brain tumors and biologic correlates of immunotherapy clinical trials. Dr. Plant has completed extra training in translational research including the Program for Clinical Effectiveness at the Harvard School of Public Health and the Markers in Cancer Course in Bethesda, MD May 2016. Dr. Plant was awarded a K12 NCI grant for translational research in nervous system tumors and was the recipient of the Stahl Family Foundation grant for early phase clinical trials in immunotherapy for pediatric neuro-oncology. She is also the first inaugural 2020 A.M. Khokhar Research Scholar award recipient and the first inaugural 2020 Will Irwin Memorial Fund Researcher. Dr. Plant is currently conducting an investigator-initiated phase 1/2 clinical trial using combination immunotherapy for diffuse intrinsic pontine glioma, a universally fatal disease. The trial combines a novel neo-antigen heat shock protein vaccine known as rHSC-DIPGVax in combination with anti-PD1 and anti-CTLA4 checkpoint blockade. The focus of Dr. Plant’s career is developing and running early phase clinical trials based on translational research in the area of pediatric neuro-oncology with a specific interest in immunotherapy.
Trial Locations
Please visit this website regularly for updates as new locations are added.
Lurie Children’s Hospital
Chicago
What Can You Do Next?
Participating in a clinical trial is an important decision. If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.

Discuss With Your Physician
Anyone participating in a clinical trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your physician first.
Print, save, or email this page to your physician to discuss at your next visit
Contact Us
Request More Information
News
December 3, 2024
November 29, 2023
Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe
- Presentation titled “Re-186 Radiolabelled NanoLiposomes for Rare Brain and Spinal Cord Tumors”
June 8, 2023
- Plus Therapeutics announced it will exhibit at both the Society for NeuroOncology’s (SNO) Pediatric Conference, taking place June 22-24, 2023 in Washington, D.C., and the Society of Nuclear Medicine & Molecular Imaging’s (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago, Illinois.
August 21, 2021
June 10, 2021
Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference
Publications
Posters
Resources
Note: all external links
- American Brain Tumor Association
- American Cancer Society
- Brain Tumor Network
- Dictionary of Cancer Terms
- End Brain Cancer Initiative
- MedlinePlus (NIH)
- National Brain Tumor Society
- National Cancer Institute
- National Comprehensive Cancer Network
- Support Groups Listing
- The Brain Tumour Charity
- Trial Connect
- VirtualTrials.com
- Voices Against Brain Cancer
Updates
About Radiotherapeutics: Advancing Technology
A Novel Radiotherapeutic Platform Targeting Complex Tumors with Precision At Plus Therapeutics, we’re pioneering a next-generation radiotherapeutic platform designed to deliver targeted cancer treatment with high precision and minimal toxicity. Our platform is powered...
REYOBIQ™: The Future of CNS Cancer Care
REYOBIQ™: A Promising Radiotherapeutic Advancing Treatment for Glioblastoma, Leptomeningeal Metastases, and Pediatric Brain Cancers At Plus Therapeutics, we’re advancing the future of cancer care with REYOBIQ™ (rhenium-186 Re obisbemeda), our lead targeted...
Introducing REYOBIQ™
Introducing REYOBIQ™: The FDA-Accepted Proprietary Name for Plus Therapeutics’ Lead Drug Candidate Big News from Plus Therapeutics! The U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REYOBIQ™ (rhenium Re186 obisbemeda) for our...
Advancing Treatment for Leptomeningeal Metastases
Advancing Treatment for Leptomeningeal Metastases (LM): ReSPECT-LM Clinical Trial Now Enrolling Leptomeningeal metastases (LM) is a devastating complication of cancer, occurring when malignant cells spread to the cerebrospinal fluid (CSF) and leptomeninges, leading to...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Contents
- 1
- 2 Stay Updated on the Upcoming ReSPECT-PBC Clinical Trial
- 3 Fill out the form below to connect with our team and learn more about potential eligibility once enrollment opens.
- 3.1 Trial Information
- 3.2 Principal Investigators
- 3.3 Trial Locations
- 3.4 What Can You Do Next?
- 3.5 Contact Us
- 3.6 Request More Information
- 3.7 News
- 3.8
- 3.9
- 3.10
- 3.11
- 3.12
- 3.13 December 3, 2024
- 3.14 Publications
- 3.15 Resources
- 3.16 Updates
- 3.17 About Radiotherapeutics: Advancing Technology
- 3.18 REYOBIQ™: The Future of CNS Cancer Care
- 3.19 Introducing REYOBIQ™
- 3.20 Advancing Treatment for Leptomeningeal Metastases
- 3.21 No Results Found